BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
HCL will establish a joint centre of excellence (CoE) for Google Cloud with industry subject matter experts and Google Cloud-certified ideapreneurs
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The platform will provide a safe and nurturing space for women, and non-binary individuals
The company plans to expand its portfolio in regulated markets aggressively
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
Subscribe To Our Newsletter & Stay Updated
